

ribociclib (Kisqali®) film-coated tablets

SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2803	In combination with an aromatase inhibitor for the adjuvant treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer at high risk of recurrence. In pre- or perimenopausal women, or in men, the aromatase inhibitor should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	10/11/2025	
Other Decision Specified :				
Web Link : https://scottishmedicines.org.uk/media/9549/ribociclib-kisqali-final-oct-2025-for-website.pdf				

isatuximab concentrate for solution for infusion (Sarclisa®)

SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2804	in combination with bortezomib, lenalidomide, and dexamethasone, for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.	Available in line with local or regional guidance	10/11/2025	18/03/2026
Other Decision Specified :				
Web Link : https://scottishmedicines.org.uk/media/9546/isatuximab-sarclisa-final-oct-2025-for-website.pdf				

elacestrant film-coated tablets (Korserdu®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2807	as monotherapy for the treatment of postmenopausal women, and men, with estrogen receptor (ER)-positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation who have disease progression following at least one line of endocrine therapy including a CDK 4/6 inhibitor.	Not routinely available as not recommended for use in NHS Scotland	10/11/2025	22/10/2025
Other Decision Specified :				
Web Link : https://scottishmedicines.org.uk/media/9553/elacestrant-korserdu-final-oct-2025-amended-241025-for-website.pdf				
tarlatamab powder for solution for infusion (Imdylltra®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2816	treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after at least two prior lines of therapy including platinum-based chemotherapy.	Not routinely available as not recommended for use in NHS Scotland	10/11/2025	22/10/2025
Other Decision Specified :				
Web Link : https://scottishmedicines.org.uk/media/9550/tarlatamab-imdylltra-final-oct-2025-amended-311025-for-website.pdf				

mercaptamine gastro-resistant hard capsules (Procysbi®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2824	treatment of proven nephropathic cystinosis. Cysteamine reduces cystine accumulation in some cells (e.g. leukocytes, muscle and liver cells) of nephropathic cystinosis patients and, when treatment is started early, it delays the development of renal failure.	Not routinely available as there is a local preference for alternative medicines	10/11/2025	17/12/2025
Other Decision Specified :				
Web Link : https://scottishmedicines.org.uk/media/9548/mercaptamine-procysbi-resub-final-oct-2025-for-website.pdf				
guselkumab solution for injection in pre-filled pen and concentrate for solution for infusion (Tremfya®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2848	Treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy, a biologic treatment, or a Janus kinase (JAK) inhibitor.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	10/11/2025	30/03/2026
Other Decision Specified :				
Web Link : https://scottishmedicines.org.uk/media/9545/guselkumab-tremfya-uc-abb-final-oct-2025-for-website.pdf				

guselkumab solution for injection in pre-filled pen and concentrate for solution for infusion (Tremfya®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2850	For the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic treatment.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	10/11/2025	30/03/2026
Other Decision Specified :				
Web Link : https://scottishmedicines.org.uk/media/9544/guselkumab-tremfya-cd-abb-final-oct-2025-for-website.pdf				
budesonide suppository (Budenofalk®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2855	short-term treatment of mild to moderate acute ulcerative colitis limited to the rectum (ulcerative proctitis) in adult patients.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	10/11/2025	30/03/2026
Other Decision Specified :				
Web Link : https://scottishmedicines.org.uk/media/9551/budesonide-budenofalk-abb-final-oct-2025-for-website.pdf				

durvalumab concentrate for solution for infusion (Imfinzi®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2857	In combination with tremelimumab for the first-line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC).	Not routinely available as the ADTC is waiting for further advice from local clinical experts	10/11/2025	20/01/2026
Other Decision Specified :				
Web Link : https://scottishmedicines.org.uk/media/9552/durvalumab-imfinzi-resub-final-oct-2025-for-website.pdf				
melatonin prolonged-release tablets (Slenyto®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2882	treatment of insomnia in children and adolescents aged 6-17 years with attention-deficit hyperactivity disorder (ADHD) where sleep hygiene measures have been insufficient.	Not routinely available as not recommended for use in NHS Scotland	10/11/2025	22/10/2025
Other Decision Specified : Non-submission.				
Web Link : https://scottishmedicines.org.uk/media/9547/melatonin-slenyto-final-oct-2025-for-website.pdf				